The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Peptide Dendrimer–Doxorubicin Conjugate‐Based Nanoparticles as an Enzyme‐Responsive Drug Delivery System for Cancer Therapy
Abstract
Peptide dendrimers have shown promise as an attractive platform for drug delivery. In this study, mPEGylated peptide dendrimer–doxorubicin (dendrimer–DOX) conjugate‐based nanoparticle is prepared and characterized as an enzyme‐responsive drug delivery vehicle. The drug DOX is conjugated to the periphery of dendrimer via an enzyme‐responsive tetra‐peptide linker Gly‐Phe‐Leu‐Gly (GFLG). The dendrimer–DOX conjugate can self‐assemble into nanoparticle, which is confirmed by dynamic light scattering, scanning electron microscopy, and transmission electron microscopy studies. At equal dose, mPEGylated dendrimer–DOX conjugate‐based nanoparticle results in significantly high antitumor activity, and induces apoptosis on the 4T1 breast tumor model due to the evidences from tumor growth curves, an immunohistochemical analysis, and a histological assessment. The in vivo toxicity evaluation demonstrates that nanoparticle substantially avoids DOX‐related toxicities and presents good biosafety without obvious side effects to normal organs of both tumor‐bearing and healthy mice as measured by body weight shift, blood routine test, and a histological analysis. Thus, the mPEGylated peptide dendrimer–DOX conjugate‐based nanoparticle may be a potential nanoscale drug delivery vehicle for the breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Enzyme-responsive nanoparticles for drug release and diagnostics
de la Rica, R., Aili, D., & Stevens, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.002 · Cited by 765
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Enzyme responsive drug delivery systems in cancer treatment
Shahriari, M., Zahiri, M., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.004 · Cited by 415
Star polymers: Advances in biomedical applications
Wu, W., Wang, W., & Li, J. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.02.002 · Cited by 407
Song, Y., Li, Y., Xu, Q., & Liu, Z. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117495 · Cited by 258
Recent advances in dendrimer-based nanoplatform for cancer treatment: A review
Ambekar, R. S., Choudhary, M., & Kandasubramanian, B. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.109546 · Cited by 126
Metadata
- Authors
- Zhang, C., Pan, D., Luo, K., She, W., Guo, C., Yang, Y., & Gu, Z.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2014-04-06
- Volume
- 3
- Issue
- 8
- Pages
- 1299-1308
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2017778740
- Cited by
- 163
- References
- 5
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.